Lung Cancer News

Lung cancer remains the No. 1 cause of cancer-related death worldwide.

The FDA granted accelerated approval to capmatinib for treatment of certain patients with metastatic non-small cell lung cancer.

Blacks and Hispanics appeared less likely than non-Hispanic whites to receive guideline-recommended PET/CT imaging at the time of lung cancer diagnosis, according to results of a study published in Journal of the National Cancer Institute.

The addition of pemetrexed plus platinum chemotherapy to the immune checkpoint inhibitor pembrolizumab showed manageable toxicity among patients metastatic nonsquamous non-small cell lung cancer, according to results of a post-hoc analysis of the KEYNOTE-189 trial presented at the virtual American Association for Cancer Research Annual Meeting.

Lorlatinib appeared to be an effective treatment for non-small cell lung cancer with ALK resistance mutations, regardless of EML4-ALK variants, according to results of a study presented at the virtual American Association for Cancer Research Annual Meeting.

The FDA approved an additional recommended dosage of pembrolizumab, authorizing its use at 400 mg every 6 weeks.

The investigational MET inhibitor capmatinib appeared effective for treatment of certain patients with metastatic non-small cell lung cancer, including those with brain metastases, according to cohort analyses of the phase 2 GEOMETRY mono-1 study presented at the virtual American Association for Cancer Research Annual Meeting.

The immune checkpoint inhibitor camrelizumab showed clinically significant activity when combined with apatinib among patients with chemosensitive and chemoresistant extensive-stage small cell lung cancer, according to phase 2 results of the randomized phase 2 PASSION trial presented at the virtual American Association for Cancer Research Annual Meeting.

Individuals with cancer and COVID-19 infection appeared at higher risk for severe outcomes than cancer-free individuals with the novel coronavirus, according to results of a multicenter study presented at the virtual American Association for Cancer Research Annual Meeting.

Mortality appeared unexpectedly high among individuals with lung cancer and COVID-19 infection, according to international registry data presented at the virtual American Association for Cancer Research Annual Meeting.